---
title: "Lysergide (DT120) in Generalized anxiety disorder: Selective serotonin reuptake inhibitors"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Selective serotonin reuptake inhibitors. Topics: NICE guideline: an SSRI as the first drug treatment, with sertraline first; NICE guideline: precautions with SSRIs; WFSBP guideline: SSRIs and SNRIs as first-line medications; CANMAT guideline: first-line, second-line, and third-line agents; 15 further topics. 19 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/selective-serotonin-reuptake-inhibitors"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Selective serotonin reuptake inhibitors

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Selective Serotonin Reuptake Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

### NICE guideline: an SSRI as the first drug treatment, with sertraline first

> “If a person with GAD chooses drug treatment, offer a selective serotonin reuptake inhibitor (SSRI). Consider offering sertraline first because it is the most cost-effective drug, but note that at the time of publication (January 2011) sertraline did not have UK marketing authorisation for this indication.”
> “Review the effectiveness and side effects of the drug every 2 to 4 weeks during the first 3 months of treatment and every 3 months thereafter. [2011]”
> “If the drug is effective, advise the person to continue taking it for at least a year as the likelihood of relapse is high. [2011]”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.2-2"></a>

### NICE guideline: precautions with SSRIs

> “the risk of activation with SSRIs and SNRIs, with symptoms such as increased anxiety, agitation and problems sleeping”
> “the gradual development, over 1 week or more, of the full anxiolytic effect”
> “Take into account the increased risk of bleeding associated with SSRIs, particularly for older people or people taking other drugs that can damage the gastrointestinal mucosa or interfere with clotting (for example, non-steroidal anti-inflammatory drugs [NSAIDS] or aspirin).”
> “warn them that these drugs are associated with an increased risk of suicidal thinking and self-harm in a minority of people under 30 and”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.2-3"></a>

### WFSBP guideline: SSRIs and SNRIs as first-line medications

> “Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are first-line medications.”

Source: [Bandelow et al. (2023)](https://www.tandfonline.com/doi/full/10.1080/15622975.2022.2086295)

<a id="topic-2.2.2.1.2-4"></a>

### CANMAT guideline: first-line, second-line, and third-line agents

> “Agomelatine, duloxetine, escitalopram, paroxetine, paroxetine CR, pregabalin, sertraline, venlafaxine XR”
> “Citalopram, divalproex chrono, fluoxetine, mirtazapine, trazodone”
> “Pharmacotherapeutic approaches should begin with one of the first-line options including an SSRI such as escitalopram, paroxetine, or sertraline,”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.2-5"></a>

### BAP guideline: SSRIs as first-line pharmacological treatment

> “Consider an SSRI for first-line pharmacological treatment [A]”
> “SSRIs have ‘broad spectrum’ efficacy in both short-term and long-term treatment, and are generally well tolerated; and for these reasons are widely considered to be the first-line pharmacological approach in patients with anxiety disorders or obsessive-compulsive disorder.”
> “Advise the patient that treatment periods of up to 12 weeks may be needed to assess efficacy [S] but recognise that an absence of clinical benefit within four weeks warns that a response to unchanged treatment is unlikely [A]”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.2-6"></a>

### U.S. primary care review: SSRIs and SNRIs as first-line medications

> “SSRIs and SNRIs are recommended as first-line medications for treating GAD and PD.”
> “Antidepressants, SSRIs and SNRIs in particular, are considered first-line therapies for GAD and PD because they are effective and generally well tolerated.”
> “SSRIs and SNRIs are the mainstay of pharmacotherapy for GAD.”
> “A recent meta-analysis found that escitalopram (Lexapro), duloxetine (Cymbalta), venlafaxine, and pregabalin (Lyrica) appear to be most effective and well tolerated.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.2.1.2-7"></a>

### FDA-approved GAD indication: escitalopram

> “generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older.”
> “The recommended starting dosage of Lexapro in adults is 10 mg once daily. Depending on clinical response and tolerability, dosage may be increased to the maximum recommended dosage of 20 mg once daily at an interval of no less than 1 week.”
> “The efficacy of Lexapro in the treatment of generalized anxiety disorder (GAD) in adults was demonstrated in three, 8-week, multicenter, flexible-dose, placebo-controlled studies that compared Lexapro (10 mg to 20 mg daily) to placebo in outpatients between 18 and 80 years of age who met DSM-IV criteria for GAD. In all three studies, Lexapro showed statistically significant greater mean improvement compared to placebo on the Hamilton Anxiety Scale (HAM-A).”

Source: [Lexapro prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf)

<a id="topic-2.2.2.1.2-8"></a>

### FDA-approved GAD indication: paroxetine

> “Generalized anxiety disorder (GAD) in adults”
> “The recommended starting PAXIL dosage in adult patients with generalized anxiety disorder (GAD) is 10 mg once daily. After one week, increase the PAXIL dosage to 20 mg once daily.”
> “There is not sufficient evidence to suggest a greater benefit with a PAXIL dosage higher than 20 mg once daily”
> “The effectiveness of PAXIL in the treatment of generalized anxiety disorder (GAD) in adults was demonstrated in two 8-week, multicenter, placebo-controlled studies (Studies GAD-1 and GAD-2) of adult outpatients with GAD (DSM-IV).”
> “A third study, a flexible-dose study (Study GAD-3) that compared PAXIL 20 mg to 50 mg once daily to placebo once daily, did not demonstrate statistically significant superiority of PAXIL over placebo on the HAM-A total score, the primary outcome.”
> “Patients who were randomized to receive PAXIL experienced a statistically significantly lower relapse rate over the subsequent 24 weeks compared to those who were randomized to receive placebo.”

Source: [Paxil prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020031s081lbl.pdf)

<a id="topic-2.2.2.1.2-9"></a>

### FDA-approved agents and SSRIs without a GAD indication

> “As an FDA-approved treatment for GAD in adults, immediate release paroxetine has been studied extensively and multiple studies support its efficacy in adults with GAD.”
> “Escitalopram has been approved by the FDA for the treatment of GAD in adults, and both escitalopram and citalopram have been evaluated in adults with GAD.”
> “In a double-blind, placebo-controlled maintenance study, patients were treated with fixed-dose escitalopram (20 mg/day) over the course of 24–76 weeks, and re-randomization to placebo was associated with a significantly higher risk of relapse (OR: 4; 56% vs. 19%; log-rank test, p<0.001).”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

<a id="topic-2.2.2.1.2-10"></a>

### Network meta-analysis: escitalopram, sertraline, fluoxetine, and paroxetine

> “This analysis is based on 89 trials, which included 25 441 patients randomly assigned to 22 different active drugs or placebo.”
> “Primary outcomes were efficacy (mean difference [MD] in change in Hamilton Anxiety Scale Score) and acceptability (study discontinuations for any cause).”
> “escitalopram (MD -2·45, 95% CrI -3·27 to -1·63) were more efficacious than placebo with relatively good acceptability.”
> “Mirtazapine, sertraline, fluoxetine, buspirone, and agomelatine were also found to be efficacious and well tolerated but these findings were limited by small sample sizes.”
> “Likewise, paroxetine and benzodiazepines were effective but also poorly tolerated when compared with placebo.”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="topic-2.2.2.1.2-11"></a>

### Meta-analysis of SSRIs, SNRIs, and benzodiazepines against placebo: effect sizes and response rates

> “A comprehensive literature search yielded 54 articles reporting 56 unique studies with 12,655 participants treated with either pill placebo (6,191 participants), SSRIs (16 trials, 2,712 participants), SNRIs (17 trials, 2,603 participants), or BZs (23 trials, 1,149 participants).”
> “SSRIs (Hedges’ g = 0.33) and SNRIs (Hedges’ g = 0.36) demonstrated significantly lower effect sizes than BZs (Hedges’ g = 0.50).”
> “Randomized-controlled trials suggest that 60-75% of patients respond to SSRIs, compared to 40-60% of patients receiving placebo, with similar response rates for SNRIs and BZs”
> “Side effects of SSRIs during the initial weeks of treatment include nausea, dizziness, headaches, jitteriness, sleep difficulties, and gastrointestinal disturbances.”

Source: [Gomez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/)

<a id="topic-2.2.2.1.2-12"></a>

### Escitalopram compared with paroxetine: adverse events and discontinuation

> “A second and longer study (24 weeks) involved double-blind treatment with escitalopram (n=60; 10–20 mg/day) or paroxetine (n=61; 20–0 mg/day) and, while no differences were observed with regard to improvement in anxiety symptoms, treatment-emergent adverse events were more frequent in paroxetine-treated patients compared to those randomized to escitalopram (88.7% vs. 77.0%).”
> “Additionally, significantly fewer escitalopram- compared to paroxetine-treated patients discontinued due to adverse events (6.6% vs. 22.6%; p=0.02)”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

<a id="topic-2.2.2.1.2-13"></a>

### Adverse reactions with escitalopram in adult GAD trials

> “The most commonly observed adverse reactions in Lexapro patients (incidence of approximately 5% or greater and approximately twice the incidence in placebo patients) were nausea, ejaculation disorder (primarily ejaculatory delay), insomnia, fatigue, decreased libido, and anorgasmia.”
> “Among the 429 GAD patients who received Lexapro 10 to 20 mg/day in placebo-controlled trials, 8% discontinued treatment due to an adverse event, as compared to 4% of 427 patients receiving placebo.”

Source: [Lexapro prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf)

<a id="topic-2.2.2.1.2-14"></a>

### Adverse reactions with escitalopram in adult GAD trials: incidence table

| Adverse reaction | Lexapro (N=429) | Placebo (N=427) |
| --- | --- | --- |
| Headache | “24%” | “17%” |
| Nausea | “18%” | “8%” |
| Ejaculation disorder | “14%” | “2%” |
| Somnolence | “13%” | “7%” |
| Insomnia | “12%” | “6%” |
| Dry mouth | “9%” | “5%” |
| Fatigue | “8%” | “2%” |
| Libido decreased | “7%” | “2%” |
| Anorgasmia | “6%” | “<1%” |

Source: [Lexapro prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf)

<a id="topic-2.2.2.1.2-15"></a>

### Adverse reactions with paroxetine in adult GAD trials

> “In clinical studies in adults with MDD, SAD, OCD, PD, GAD, and PTSD, 20% (1,199/6,145), 16% (84/522), 12% (64/542), 9% (44/469), 11% (79/735), and 12% (79/676) of PAXIL-treated patients, respectively, discontinued treatment due to an adverse reaction.”
> “Placebo and PAXIL 20 mg and 40 mg once daily in the treatment of adults with GAD were asthenia, constipation, and abnormal ejaculation.”
> “During clinical trials of GAD and PTSD, gradual decreases in the daily PAXIL dosage by 10 mg/day at weekly intervals followed by 1 week at 20 mg/day was used before treatment was discontinued.”

Source: [Paxil prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020031s081lbl.pdf)

<a id="topic-2.2.2.1.2-16"></a>

### Boxed warning and discontinuation syndrome in SSRI labeling

> “Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors”
> “During marketing of Lexapro and other SSRIs, there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania.”

Source: [Lexapro prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf)

<a id="topic-2.2.2.1.2-17"></a>

### BAP guideline: adverse effects and discontinuation syndrome with SSRIs

> “However SSRIs have potentially troublesome adverse effects, including initial increased nervousness, insomnia, nausea and sexual dysfunction”
> “When stopped abruptly, and even when tapered slowly, SSRIs can produce a discontinuation syndrome characterised by dizziness, insomnia and flu-like symptoms”
> “this seems more likely with paroxetine and least likely with fluoxetine”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.2-18"></a>

### Relapse after discontinuation: continuation trials

> “have demonstrated significantly lower relapse rates over six to 18 months in the range of 10-20% with active treatment compared to 40-56% with placebo.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

> “Although approximately 16% of patients relapse despite continued use of antidepressants, discontinuing antidepressants before one year leads to symptom relapse in up to 50% of patients being treated with an SSRI or SNRI.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.2.1.2-19"></a>

### Relapse after discontinuation: meta-analysis of relapse prevention trials, SSRI subgroup

| Subgroup | Number of studies | Odds ratio of relapse, placebo relative to continued antidepressant (95% CI) |
| --- | --- | --- |
| All anxiety disorders | “28” | “3.11 (2.48 to 3.89)” |
| Generalised anxiety disorder (DSM-IV) | “6” | “4.20 (2.42 to 7.28)” |
| SSRI | “21” | “2.86 (2.17 to 3.78)” |

Source: [Batelaan et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5596392/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
